Abstract | OBJECTIVE: STUDY DESIGN: RESULTS: CONCLUSIONS: Proteomic markers are used to improve the diagnosis and prognosis of PH but, as demonstrated here, can be altered in genetically unique populations such as individuals with Down syndrome. This further suggests that clinical biomarkers should be evaluated in unique groups with the development of population-specific nomograms.
|
Authors | Megan Griffiths, Jun Yang, Dhananjay Vaidya, Melanie Nies, Stephanie Brandal, D Dunbar Ivy, Francis Hickey, Kristine Wolter-Warmerdam, Eric D Austin, Mary Mullen, Michael W Pauciulo, Katie A Lutz, Erika B Rosenzweig, Russel Hirsch, Delphine Yung, William C Nichols, Allen D Everett |
Journal | The Journal of pediatrics
(J Pediatr)
Vol. 241
Pg. 68-76.e3
(02 2022)
ISSN: 1097-6833 [Electronic] United States |
PMID | 34687693
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2021. Published by Elsevier Inc. |
Chemical References |
- Biomarkers
- Endostatins
- Galectin 3
- Intercellular Signaling Peptides and Proteins
- Interleukin-6
- Peptide Fragments
- Receptors, Interleukin-1
- hepatoma-derived growth factor
- pro-brain natriuretic peptide (1-76)
- Natriuretic Peptide, Brain
|
Topics |
- Adolescent
- Biomarkers
(blood)
- Case-Control Studies
- Child
- Child, Preschool
- Down Syndrome
(complications)
- Endostatins
(blood)
- Female
- Galectin 3
(blood)
- Humans
- Hypertension, Pulmonary
(blood, complications)
- Intercellular Signaling Peptides and Proteins
(blood)
- Interleukin-6
(blood)
- Male
- Natriuretic Peptide, Brain
- Peptide Fragments
- Receptors, Interleukin-1
(blood)
|